Answers are grounded in this paper and cite their sources.
This case commentary examines Novartis AG v. Union of India, (2013) 6 SCC 1, a landmark decision on pharmaceutical patentability under Section 3(d) of the Patents Act, 1970. Novartis sought a patent for the beta crystalline form of Imatinib Mesylate, used to treat chronic myeloid leukaemia, claiming enhanced bioavailability. The Supreme Court rejected the claim, holding that "efficacy" for medicines means therapeutic efficacy, not merely improved physical properties or bioavailability. The judgment establishes a strict standard against evergreening, requiring demonstrable enhancement of curative effect for new forms of known substances. It balances intellectual-property protection with public health and access to affordable generic medicines.
No takes yet. Share an insight, caveat, or question.
Chandan Sha (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: